3,4-dihydro-5-[3,5-bis(trifluoromethyl)phenyl]-2H-pyrrole | 334477-35-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-dihydro-5-[3,5-bis(trifluoromethyl)phenyl]-2H-pyrrole
• 英文别名: 5-(3,5-Bis(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrrole；5-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrrole
• CAS: 334477-35-9
• 化学式: C₁₂H₉F₆N
• 分子量: 281.201
• InChiKey: OPEDGGJYELIIKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-5-[3,5-bis(trifluoromethyl)phenyl]-2H-pyrrole 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 2-(3,5-bis(trifluoromethyl)phenyl)-1-(naphthalen-2-ylsulfonyl)pyrrolidine
  参考文献：
  名称：

  Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK1 receptor antagonists

  摘要：

  A focused exploration targeting conformationally restricted analogues of Vestipitant, resulted in the discovery of novel, in vitro potent NK1 antagonists. In particular, two of the compounds reported exhibited a good pharmacokinetic (PK) profile and produced anxiolytic-like effects in the gerbil foot tapping (GFT) in vivo model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.078
• 作为产物：
  描述：

  3-(3,5-Bis-trifluoromethyl-benzoyl)-1-vinyl-pyrrolidin-2-one 在 盐酸 、 potassium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 生成 3,4-dihydro-5-[3,5-bis(trifluoromethyl)phenyl]-2H-pyrrole
  参考文献：
  名称：

  Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK1 receptor antagonists

  摘要：

  A focused exploration targeting conformationally restricted analogues of Vestipitant, resulted in the discovery of novel, in vitro potent NK1 antagonists. In particular, two of the compounds reported exhibited a good pharmacokinetic (PK) profile and produced anxiolytic-like effects in the gerbil foot tapping (GFT) in vivo model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.078

文献信息

• Enantioselective Imine Reduction Catalyzed by Phosphenium Ions
  作者：Travis Lundrigan、Erin N. Welsh、Toren Hynes、Chieh-Hung Tien、Matt R. Adams、Kayelani R. Roy、Katherine N. Robertson、Alexander W. H. Speed

  DOI：10.1021/jacs.9b07293

  日期：2019.9.11

  The first use of phosphenium cations in asymmetric catalysis is reported. A diazaphosphenium triflate, prepared in two or three steps on a multi-gram scale from commercially available materials catalyzes the hydroboration or hydrosilation of cyclic imines with enantiomeric ratios of up to 97:3. Catalyst loadings are as low as 0.2 mole percent. Twenty-two aryl/heteroaryl pyrrolidines and piperidines

  报道了鏻阳离子在不对称催化中的首次应用。二氮杂磷鎓三氟甲磺酸盐由市售材料以多克规模分两步或三步制备，催化对映体比例高达 97:3 的环状亚胺的硼氢化或硅氢化。催化剂负载量低至 0.2 摩尔百分比。使用该方法制备了 22 种芳基/杂芳基吡咯烷和哌啶。使用这些系统可以还原含有可以挑战过渡金属催化剂的官能团（如噻吩或吡啶环）的亚胺。
• Chemical compounds
  申请人：——

  公开号：US20030028021A1

  公开（公告）日：2003-02-06

  The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins.

  本发明涉及哌嗪衍生物、其制备方法、包含它们的制药组合物以及它们的医疗用途。这些新化合物是缓解速激肽素（包括物质P和其他神经激肽素）的拮抗剂。
• Chemical Compounds
  申请人：Alvaro Giuseppe

  公开号：US20080249108A1

  公开（公告）日：2008-10-09

  The invention relates to methods for the treatment of medical conditions comprising administering an effective amount of a compound of formula (I): wherein all variables are as defined herein.

  本发明涉及治疗医疗状况的方法，包括给予公式（I）化合物的有效量：其中所有变量在此定义。
• Piperazine compounds and pharmaceutical compositions containing them.
  申请人：GLAXO GROUP LIMITED

  公开号：EP1454901A1

  公开（公告）日：2004-09-08

  A composition comprising a compound of formula (I) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents hydrogen or a C1-4 alkyl group; R2 represents hydrogen, a C1-4 alkyl, C2-6 alkenyl_or a C3-7 cycloalkyl group; or R1 and R2 together with nitrogen and carbon atom to which they are attached respectively represent a 5-6 membered heterocyclic group; R3 represents a trifluoromethyl, a C1-4 alkyl, a C1-4 alkoxy, a trifluoromethoxy or a halogen group; R4 represents hydrogen, a (CH2)qR7 or a (CH2)rCO(CH2)pR7 group; R5 represents hydrogen, a C1-4 alkyl or a COR6 group; R7 represents hydrogen, hydroxy or NR8R9 wherein R8 and R9 represent independently hydrogen or C1-4 alkyl optionally substituted by hydroxy, or by amino; R10 represents hydrogen, a C1-4 alkyl group or R10 together with R2 represents a a C3-7 cycloalkyl group; m is zero or an integer from 1 to 3; n is zero or an integer from 1 to 3; both p and r are independently zero or an integer from 1 to 4; q is an integer from 1 to 4; provided that, when R1 and R2 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group, i) m is 1 or 2; ii) when m is 1, R is not fluorine and iii) when m is 2, the two substituents R are not both fluorine, or pharmaceutically acceptable salts or solvates thereof and a selective serotonin reuptake inhibitor.

  一种包含式 (I) 化合物的组合物 其中 R 代表卤素原子或 C1-4 烷基； R1 代表氢或 C1-4 烷基 R2 代表氢、C1-4 烷基、C2-6 烯基或 C3-7 环烷基；或 R1 和 R2 与它们分别连接的氮原子和碳原子一起代表 5-6 位杂环基团； R3 代表三氟甲基、C1-4 烷基、C1-4 烷氧基、三氟甲氧基或卤素基团； R4 代表氢、(CH2)qR7 或 (CH2)rCO(CH2)pR7 基团； R5 代表氢、C1-4 烷基或 COR6 基团； R7 代表氢、羟基或 NR8R9，其中 R8 和 R9 独立地代表氢或任选被羟基或氨基取代的 C1-4 烷基； R10 代表氢、C1-4 烷基或 R10 与 R2 一起代表 C3-7 环烷基； m 为零或 1 至 3 的整数； n 为零或 1 至 3 的整数； p 和 r 独立地均为零或 1 至 4 的整数； q 为 1 至 4 的整数；条件是 当 R1 和 R2 与氮原子和它们分别连接的碳原子一起代表 5 至 6 位杂环基团时，i) m 为 1 或 2；ii) 当 m 为 1 时，R 不为氟，iii) 当 m 为 2 时，两个取代基 R 不同时为氟，或其药学上可接受的盐或溶液，以及选择性 5-羟色胺再摄取抑制剂。
• Piperazine compounds
  申请人：GLAXO GROUP LIMITED

  公开号：EP1460066A1

  公开（公告）日：2004-09-22

  The present invention relates to piperazine derivatives of formula (I) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents hydrogen or a C1-4 alkyl group; R2 represents hydrogen, a C1-4 alkyl, C2-6 alkenyl_or a C3-7 cycloalkyl group; or R1 and R2 together with nitrogen and carbon atom to which they are attached respectively represent a 5-6 membered heterocyclic group; R3 represents a trifluoromethyl, a C1-4 alkyl, a C1-4 alkoxy, a trifluoromethoxy or a halogen group; R4 represents hydrogen, a (CH2)qR7 or a (CH2)rCO(CH2)pR7 group; R5 represents hydrogen, a C1-4 alkyl group; R7 represents hydrogen, hydroxy or NR8R9 wherein R8 and R9 represent independently hydrogen or C1-4 alkyl optionally substituted by hydroxy, or by amino; R10 represents hydrogen, a C1-4 alkyl I group or R10 together with R2 represents a a C3-7 cycloalkyl group; m is zero or an integer from 1 to 3; n is zero or an integer from 1 to 3; both p and r are independently zero or an integer from 1 to 4; q is an integer from 1 to 4; provided that, when R1 and R2 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group, i) m is 1 or 2; ii) when m is 1, R is not fluorine and iii) when m is 2, the two substituents R are not both fluorine, and pharmaceutically acceptable salts. and solvates thereof.

  本发明涉及式 (I) 的哌嗪衍生物 其中 R 代表卤素原子或 C1-4 烷基； R1 代表氢或 C1-4 烷基 R2 代表氢、C1-4 烷基、C2-6 烯基或 C3-7 环烷基；或 R1 和 R2 与它们分别连接的氮原子和碳原子一起代表 5-6 位杂环基团； R3 代表三氟甲基、C1-4 烷基、C1-4 烷氧基、三氟甲氧基或卤素基团； R4 代表氢、(CH2)qR7 或 (CH2)rCO(CH2)pR7 基团； R5 代表氢、C1-4 烷基； R7 代表氢、羟基或 NR8R9，其中 R8 和 R9 独立地代表氢或任选被羟基或氨基取代的 C1-4 烷基； R10 代表氢、C1-4 烷基 I 基团或 R10 与 R2 一起代表 C3-7 环烷基； m为零或 1 至 3 的整数；n 为零或 1 至 3 的整数；p 和 r 独立地均为零或 1 至 4 的整数；q 为 1 至 4 的整数；条件是，当 R1 和 R2 与氮和它们分别连接的碳原子一起代表 5 至 6 位杂环基团时，i) m 为 1 或 2；ii) 当 m 为 1 时，R 不是氟，iii) 当 m 为 2 时，两个取代基 R 不是都是氟，以及药学上可接受的盐。及其溶剂。